Beneficial Effect of Bee Venom and Its Major Components on Facial Nerve Injury Induced in Mice
Biomolecules · 2023
DOI: 10.3390/biom13040680 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Hafsa Er-Rouassi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre Borelli, Université de Paris Cité, National Centre for Scientific Research UMR 9010, 75006 Paris, France. Hauptthemen laut MEDLINE: Bee Venoms, Facial Nerve Injuries. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Peripheral nerve injury (PNI) is a health problem that affects many people worldwide. This study is the first to evaluate the potential effect of bee venom (BV) and its major components in a model of PNI in the mouse. For that, the BV used in this study was analyzed using UHPLC. All animals underwent a distal section-suture of facial nerve branches, and they were randomly divided into five groups. Group 1: injured facial nerve branches without any treatment. Group 2: the facial nerve branches were injured, and the normal saline was injected similarly as in the BV-treated group. Group 3: injured facial nerve branches with local injections of BV solution. Group 4: injured facial nerve branches with local injections of a mixture of PLA2 and melittin. Group 5: injured facial nerve branches with local injection of betamethasone. The treatment was performed three times a week for 4 weeks. The animals were submitted to functional analysis (observation of whisker movement and quantification of nasal deviation). The vibrissae muscle re-innervation was evaluated by retrograde labeling of facial motoneurons in all experimental groups. UHPLC data showed 76.90 ± 0.13%, 11.73 ± 0.13%, and 2.01 ± 0.01%, respectively, for melittin, phospholipase A2, and apamin in the studied BV sample. The obtained results showed that BV treatment was more potent than the mixture of PLA2 and melittin or betamethasone in behavioral recovery. The whisker movement occurred faster in BV-treated mice than in the other groups, with a complete disappearance of nasal deviation two weeks after surgery. Morphologically, a normal fluorogold labeling of the facial motoneurons was restored 4 weeks after surgery in the BV-treated group, but no such restoration was ever observed in other groups. Our findings indicate the potential of the use of BV injections to enhance appropriate functional and neuronal outcomes after PNI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre Borelli, Université de Paris Cité, National Centre for Scientific Research UMR 9010, 75006 Paris, France.
- Laboratory of Natural Substances, Pharmacology, Environment, Modeling, Health, and Quality of Life (SNAMOPEQ), Department of Biology, Faculty of Sciences Dhar Mehraz, Sidi Mohamed Ben Abdellah University, Fez 30000, Mor…
- The Higher Institute of Nursing Professions and Health Techniques, Fez 30000, Morocco.
- Centro de Investigação de Montanha, Instituto Politécnico de Bragança, Campus de Santa Apolónia, 5300-252 Bragança, Portugal.
ORCID-Profile: Meryem Bakour, Miguel Vilas-Boas, Soraia Falcão
Zitieren
APA
Er-Rouassi, H., Bakour, M., Touzani, S., Vilas-Boas, M., Falcão, S., Vidal, C., & Lyoussi, B. (2023). Beneficial Effect of Bee Venom and Its Major Components on Facial Nerve Injury Induced in Mice. Biomolecules. https://doi.org/10.3390/biom13040680
Vancouver
Er-Rouassi H, Bakour M, Touzani S, Vilas-Boas M, Falcão S, Vidal C, et al. Beneficial Effect of Bee Venom and Its Major Components on Facial Nerve Injury Induced in Mice. Biomolecules. 2023. doi:10.3390/biom13040680
BibTeX
@article{ErRouassi2023,
author = {Er-Rouassi, Hafsa and Bakour, Meryem and Touzani, Soumaya and Vilas-Boas, Miguel and Falcão, Soraia and Vidal, Catherine and Lyoussi, Badiaa},
title = {Beneficial Effect of Bee Venom and Its Major Components on Facial Nerve Injury Induced in Mice},
journal = {Biomolecules},
year = {2023},
doi = {10.3390/biom13040680}
}
EUVIMED